Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Xeris Biopharma Holdings, Inc. (XERS)

1.4   0.08 (6.06%) 11-25 13:00
Open: 1.34 Pre. Close: 1.32
High: 1.42 Low: 1.315
Volume: 306,106 Market Cap: 190(M)

Technical analysis

as of: 2022-11-28 8:52:41 AM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.78     One year: 1.98
Support: Support1: 1.25    Support2: 1.03
Resistance: Resistance1: 1.52    Resistance2: 1.7
Pivot: 1.4
Moving Average: MA(5): 1.32     MA(20): 1.44
MA(100): 1.57     MA(250): 1.98
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 21.6     %D(3): 15.3
RSI: RSI(14): 47.8
52-week: High: 3.17  Low: 1.19
Average Vol(K): 3-Month: 860 (K)  10-Days: 709 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ XERS ] has closed above bottom band by 49.1%. Bollinger Bands are 11.3% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.42 - 1.43 1.43 - 1.43
Low: 1.3 - 1.31 1.31 - 1.31
Close: 1.39 - 1.4 1.4 - 1.41

Company Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. The company markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Headline News

Sun, 27 Nov 2022
As Gen X and Boomers Age, They Confront Living Alone - The New York Times

Thu, 24 Nov 2022
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab - Zacks Investment Research

Wed, 23 Nov 2022
Health Care Sector Update for 11/23/2022: STRM, JNJ, XERS, HZNP, BMRN - Nasdaq

Tue, 22 Nov 2022
Will Gen X ever have a president or has it missed its turn? - Washington Examiner

Fri, 18 Nov 2022
UNPACKING THE BACKPACK - The kids are all right - The Villager

Thu, 17 Nov 2022
House Democrats move from octogenarians to Gen X - CNN

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 136 (M)
Shares Float 120 (M)
% Held by Insiders 2.6 (%)
% Held by Institutions 45.5 (%)
Shares Short 6,290 (K)
Shares Short P.Month 6,600 (K)

Stock Financials

EPS -1.42
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0.4
Profit Margin (%) -134.5
Operating Margin (%) -96.5
Return on Assets (ttm) -27.4
Return on Equity (ttm) -504.1
Qtrly Rev. Growth 168.8
Gross Profit (p.s.) 0.26
Sales Per Share 0.72
EBITDA (p.s.) -0.63
Qtrly Earnings Growth 0
Operating Cash Flow -116 (M)
Levered Free Cash Flow -37 (M)

Stock Valuations

PE Ratio -0.99
PEG Ratio 0
Price to Book value 3.41
Price to Sales 1.93
Price to Cash Flow -1.65

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.